Cadila Healthcare

From Wikipedia, the free encyclopedia
  (Redirected from Zydus Cadila)
Jump to navigation Jump to search

Zydus dedicated life Healthcare Limited
Public (BSE532321)
Traded asBSE:532321
IndustryPharmaceuticals
Founded1952
FounderRamanbhai Patel
HeadquartersAhmedabad, India
Key people
Pankaj R. Patel, Chairman, Sharvil P. Patel, Managing Director
RevenueIncreaseINR 119.05 Billion (2018) [1]
IncreaseINR 17.76 Billion (2018)
Number of employees
13180 (2015)
Websitewww.zyduscadila.com

Cadila Healthcare Ltd (BSE532321) is an Indian pharmaceutical company headquartered at Ahmedabad in Gujarat state of western India. The company is one of the leading pharmaceutical companies in India,[2] with INR 119.05 Billion revenue (2018).[1] It is a manufacturer of generic drugs.[3] In 2019, injectable ketorolac tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth.

History[edit]

Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company.

In 1995 the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals Ltd., and Cadila Healthcare Ltd became the Patel family's holding company. Cadila Healthcare had its initial public offering on the Bombay Stock Exchange in 2000 as stock code 532321.

In 2015 the company acquired another Indian pharmaceutical company called German Remedies. On 25 June 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda.[4]

In 2010, Cadila Healthcare received a Wellcome Trust Award under the "R&D for Affordable Healthcare in India" initiative.

In 2014, Cadila Healthcare launched the world's first adalimumab biosimilar under the brand name Exemptia at one-fifth the originator's price.[5] Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in treatment of Diabetic Dyslipidemia under brand name "Lipaglyn". SoviHep is the first sofosbuvir brand launched in India by Zydus in year 2015.[3]

Products[edit]

From nine pharmaceutical production operations in India as well as a Zydus Cadila develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products. Starting from late 2015, having concluded a voluntary license agreement with Gilead, the company also produces the generics for hepatitis C treatment (i.e. sofosbuvir, distributed under the brand name SoviHep).[6]

The company makes active pharmaceutical ingredients at three sites in India:

Ankleshwar plants

Zydus Cadila's plant complex at Ankleshwar in Bharuch District of Gujarat, has been producing drug material since 1972. There are around 12 plants in the complex, which is ISO 9002 and ISO 14001 certified approved by the U.S. Food and Drug Administration (FDA). Total plant capacity at Ankleshwar is around 180 million tonnes.

Vadodara plant

Zydus Cadila's plant at Dhabhasa, in Vadodara District's Padra taluka (in the eastern part of the district) in Gujarat, was commissioned in 1997 by a company called Banyan Chemicals, and acquired by Zydus Cadila in 2002. The plant has a 90 million tonne capacity. It is approved by the U.S. FDA and is also approved to World Health Organization (WHO) good manufacturing practice (GMP) standards.

Patalganga plant

Zydus Cadila acquired an API plant at Patalganga in Maharashtra state, 70 km from Mumbai, about 859 km from Nagpur, in the 2001 German Remedies deal. This plant operates to WHO GMP standards.

Others[edit]

Navi Mumbai plant

This operation, at Navi Mumbai in Maharashtra, is a 50/50 joint venture with Nycomed Pharma of the United States, makes intermediates of the drug pantoprazole.

Mumbai Business Office

This office houses Business Unit India - 2 or German Remedies. This office belonged to German Remedies (I) Ltd. This company was acquired in 2000. This was the biggest takeover in the history of the Indian pharmacological industry.

Goa plants

The company's plants at Ponda in the southern Indian state of Goa do formulation work as well as manufacture oncology drugs and a herbal laxative branded Agiolax based on Psyllium seeds. These plants also belonged to German Remedies (I) Ltd. and now are part of Business Unit - Manufacturing of the company.

Baddi plant

In 2004 Zydus commissioned at formulation plant at Baddi, in Himachal Pradesh state of northern India, which makes solid oral pharmaceuticals.

Sikkim plant

In 2008 Zydus commissioned at formulation plant at Majhitar, in Sikkim state of eastern India. The Sikkim plant makes solid oral pharmaceuticals and hormones and almost all the domestic formulations for the company.

In Gujarat, India[edit]

Dabhasa plant

Zydus Cadila's API/Bulk Drug Plant in a village about 20 kilometers South from Vadodara houses one of the largest process research (API) centers in that country. This plant belonged to Banyan Chemicals which was acquired by Zydus in 2003

Vatva plant

Zydus Cadila's plant at Vatva, an industrial suburb of Ahmedabad, makes products for Animal Health care division of the company.

Changodar plant

Zydus Cadila's plant at Changodar, 20 kilometres from Ahmedabad on the city's outskirts, until 2015 called Zyfine, manufactures fine chemicals. Zydus is currently[when?] constructing a facility at Changodar to make vaccines for hepatitis B and rabies.

Zydus Research Centre (ZRC) (Changodar)

Zydus's NCE, NME, MBE research facility is the largest of its kind in India, with more than 500 post graduate scientists.

Zydus Hospira Oncology Pvt. Ltd. (SEZ, Matoda)

Zydus's joint venture with Hospira Inc. of US manufactures Anti Cancer Injectables at this plant. This plant is also U.S. FDA approved and situated in Special Economy Zone, about 25 kilometers from Ahmedabad. This SEZ is developed by Zydus Infrastructure Pvt. Ltd., another group company of Zydus.

Zydus – BSV (SEZ, Matoda)

Zydus's joint venture with Bharat Serum and Vaccine Ltd.'s Plant is another facility located in the same SEZ.

Zydus Technologies Ltd.(SEZ, Matoda)

Zydus's joint venture with Noveltech Inc. The plant is another facility in the same SEZ for Novel Drug Delivery Systems.

Nutralite Manufacturing Facility (Changodar)

Zydus manufactures and sells Nutralite (a butter substitute) under the banner of Zydus Wellness Ltd. This company also manufactures and sells brands as SugraFree, Everyouth, Everyouth Men'z and D'lite.

Recalls[edit]

In 2019, injectable ketorolac tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth.[7]

Corporate control[edit]

Zydus Cadila's major shareholder remains the Patel family. Pankaj Patel (born 1951), son of the founder, is Chairman of the company. In 2004 Pankaj Patel was included by Forbes magazine in its annual List of India's richest people. Forbes estimated Patel's net worth at US$510m, making him India's 26th richest person.[8]

References[edit]

  1. ^ a b "Cadila Healthcare Limited: Annual Report 2014-15" (PDF). www.bseindia.com.
  2. ^ "A Complete Overview on Cadila Healthcare, a growing and popular company in India". business.mapsofindia.com. 21 June 2011. Retrieved 4 February 2009.
  3. ^ a b "Zydus launches SoviHep - the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences". The Hindu Business Line. 17 March 2015. Retrieved 29 December 2017.
  4. ^ Company Overview of Química e Farmacêutica Nikkho do Brasil Ltda Bloomberg
  5. ^ Zydus Cadila launches biosimilar of AbbVie's Humira in India The Economic Times 9 December 2014
  6. ^ "Hepatitis C treatment in India for less than $1000". hep-c-news.com. Hep C News. 11 July 2016. Archived from the original on 16 September 2016.
  7. ^ "Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance". Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL). This product was manufactured by Zydus (Cadila Healthcare Limited) and distributed by Sagent Pharmaceuticals, Inc. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP to the user level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.
  8. ^ "Forbes.com: India's Richest". www.forbes.com. Retrieved 4 February 2009.

External links[edit]